Sumitomo Life Insurance Co. lowered its position in Eli Lilly And Co (NYSE:LLY) by 1.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 29,883 shares of the company’s stock after selling 509 shares during the period. Sumitomo Life Insurance Co.’s holdings in Eli Lilly And Co were worth $3,207,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. BlackRock Inc. lifted its holdings in shares of Eli Lilly And Co by 1.3% in the second quarter. BlackRock Inc. now owns 66,644,897 shares of the company’s stock valued at $5,686,808,000 after purchasing an additional 864,451 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Eli Lilly And Co by 7.5% in the second quarter. Janus Henderson Group PLC now owns 10,008,768 shares of the company’s stock valued at $854,049,000 after purchasing an additional 700,582 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Eli Lilly And Co by 37.8% in the second quarter. Morgan Stanley now owns 4,473,537 shares of the company’s stock valued at $381,727,000 after purchasing an additional 1,227,888 shares in the last quarter. Bank of Montreal Can lifted its holdings in shares of Eli Lilly And Co by 4.6% in the third quarter. Bank of Montreal Can now owns 4,330,654 shares of the company’s stock valued at $464,722,000 after purchasing an additional 191,374 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in shares of Eli Lilly And Co by 2.3% in the second quarter. Swiss National Bank now owns 3,851,143 shares of the company’s stock valued at $328,618,000 after purchasing an additional 84,800 shares in the last quarter. Institutional investors and hedge funds own 76.56% of the company’s stock.

Eli Lilly And Co stock traded down $0.55 during mid-day trading on Thursday, reaching $113.04. 25,061 shares of the company’s stock were exchanged, compared to its average volume of 4,207,350. The firm has a market capitalization of $115.25 billion, a P/E ratio of 26.45, a price-to-earnings-growth ratio of 1.88 and a beta of 0.29. Eli Lilly And Co has a one year low of $73.69 and a one year high of $116.61. The company has a current ratio of 1.40, a quick ratio of 1.09 and a debt-to-equity ratio of 0.79.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings results on Tuesday, July 24th. The company reported $1.50 EPS for the quarter, topping the Zacks’ consensus estimate of $1.30 by $0.20. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The business had revenue of $6.36 billion for the quarter, compared to analyst estimates of $6.05 billion. During the same period last year, the company posted $1.11 earnings per share. Eli Lilly And Co’s quarterly revenue was up 9.1% compared to the same quarter last year. Analysts predict that Eli Lilly And Co will post 5.47 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Shareholders of record on Thursday, November 15th will be given a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a yield of 1.99%. The ex-dividend date of this dividend is Wednesday, November 14th. Eli Lilly And Co’s dividend payout ratio is currently 52.57%.

In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 7,000 shares of the firm’s stock in a transaction on Thursday, October 4th. The stock was sold at an average price of $114.64, for a total value of $802,480.00. Following the completion of the sale, the senior vice president now directly owns 45,224 shares of the company’s stock, valued at $5,184,479.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 14,632 shares of the firm’s stock in a transaction on Monday, October 8th. The stock was sold at an average price of $115.91, for a total value of $1,695,995.12. Following the completion of the sale, the insider now directly owns 119,191,172 shares of the company’s stock, valued at $13,815,448,746.52. The disclosure for this sale can be found here. Insiders sold 1,785,575 shares of company stock valued at $180,166,130 over the last three months. Company insiders own 0.11% of the company’s stock.

A number of research analysts have recently weighed in on the company. DZ Bank restated a “hold” rating on shares of Eli Lilly And Co in a report on Friday, June 22nd. Barclays raised their target price on Eli Lilly And Co from $112.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, October 12th. Cantor Fitzgerald set a $100.00 target price on Eli Lilly And Co and gave the company a “buy” rating in a report on Tuesday, July 24th. ValuEngine upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating in a report on Monday, October 8th. Finally, Credit Suisse Group set a $84.00 price target on Eli Lilly And Co and gave the stock a “hold” rating in a report on Friday, July 13th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and twelve have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $109.80.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: The benefits and drawbacks of dollar cost averaging

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.